GSK PLC SEC Filings

GSK plc reported the purchase of 335,358 ordinary shares on 10 July 2025 under its ongoing buy-back programme executed by Merrill Lynch International. Prices ranged from 1,430.50p to 1,462.00p with a volume-weighted average price of 1,449.95p.

Since the programme’s launch on 4 June 2025, GSK has repurchased 11,753,770 shares. Following the latest purchase the company now holds 229,888,153 shares in treasury, representing 5.63 % of total voting rights, leaving 4,085,493,697 shares outstanding (ex-treasury).

The filing consists mainly of the aggregate data above and a detailed schedule of individual trades executed on the London Stock Exchange. No new guidance, financial results or material corporate actions were disclosed.

GSK plc filed a Form 6-K detailing activity under its ongoing share repurchase programme. On 09 July 2025 the company repurchased 473,780 ordinary shares (nominal value 31⅓p) through Merrill Lynch International at prices between 1,403.50p – 1,430.00p, resulting in a volume-weighted average price of 1,422.07p. The shares will be held in treasury.

Since the non-discretionary agreement started on 4 June 2025, GSK has acquired 11,418,412 shares. Following the latest purchase, treasury holdings rise to 229,552,795 shares, representing 5.62 % of total voting rights. Shares in issue (excluding treasury) now stand at 4,085,829,055.

• Daily buyback equates to roughly 0.012 % of outstanding shares; cumulative purchases since 4 June equal ~0.28 %.
• Removal of shares from circulation slightly improves earnings per share and signals management’s continued capital-return commitment.
• Updated share count (4.09 bn) should be used for ownership disclosure calculations under FCA DTR rules.

GSK plc (GSK) filed a Form 6-K detailing activity under its authorised share repurchase programme.

• Date of purchase: 8 July 2025
• Shares bought: 480,940 ordinary shares of 31 ¼ pence each
• Price range: 1,388.50 p – 1,416.50 p; VWAP: 1,405.17 p
• Broker: Merrill Lynch International, acting under a non-discretionary agreement dated 4 June 2025
• Programme progress: Since 4 June 2025 the company has repurchased 10,944,632 shares
• Treasury position: Treasury shares now total 229,079,015, representing 5.61 % of voting rights
• Shares in issue (ex-treasury): 4,086,302,835; this is also the new denominator for FCA DTR 5 calculations

The filing includes a complete schedule of trades executed on the London Stock Exchange (XLON). No trades occurred on CBOE CHIX or BATE on the stated date.

Contact details for media and investor relations representatives are provided. A standard cautionary note reminds investors of forward-looking statement risks.

GSK plc disclosed the latest daily tranche of its on-market share buy-back programme in a Form 6-K for 7 July 2025.

• Shares repurchased: 485,199 ordinary shares (nominal value 31¼ p) via Merrill Lynch International.
• Price range: 1,387.50 p – 1,404.00 p; VWAP: 1,395.87 p.
• Cost of this tranche: approx. £6.8 million.
• Cumulative since programme start (4 Jun 2025): 10,463,692 shares.
• Treasury position: 228,598,075 shares, representing 5.59 % of total voting rights.
• Shares in issue (ex-treasury): 4,086,783,775.

The repurchase is executed under a non-discretionary agreement announced on 4 June 2025 and does not change the previously communicated aggregate buy-back ceiling. The information enables investors to update free-float and voting-rights calculations and signals continued capital returns, albeit in routine daily volumes.

GSK plc has completed the acquisition of BP Asset IX, Inc. from Boston Pharmaceuticals, gaining full rights to efimosfermin alfa, a Phase III–ready, once-monthly FGF21 analogue being developed for metabolic dysfunction-associated steatohepatitis (MASH) and alcohol-related liver disease (ALD). These two diseases are the leading causes of liver transplantation in the US and currently have limited treatment options.

The deal, disclosed via Form 6-K, is valued at up to US$2 billion, consisting of an upfront cash payment of US$1.2 billion and up to US$800 million in success-based milestones. In addition, GSK will assume tiered royalty obligations owed to Novartis. Management identifies efimosfermin as a "key growth opportunity" with a potential first commercial launch in 2029, and sees synergy with GSK'990, its in-house siRNA therapy for other steatotic liver disease (SLD) subsets.

Efimosfermin’s proposed antifibrotic mechanism is aimed at halting or reversing liver fibrosis in moderate to advanced MASH, including cirrhosis, and it may be positioned for combination therapy within GSK’s expanding hepatology franchise. The transaction reinforces GSK’s strategic emphasis on immune-mediated and fibro-inflammatory diseases across liver, lung and kidney.

No immediate earnings guidance changes were provided, but the large upfront payment will impact near-term cash outflows while clinical, regulatory and commercial risks remain until at least late-decade approval. Forward-looking statements are subject to the risk factors detailed in GSK’s 2024 Form 20-F and 2025 Q1 results.

GSK plc (NYSE/LSE: GSK) filed a Form 6-K disclosing the latest execution under its ongoing £5 billion share repurchase programme. On 4 July 2025 the company, via its broker Merrill Lynch International, bought 484,578 ordinary shares (nominal value 31¼ p) on the London Stock Exchange at prices between 1,388.00 p and 1,415.00 p, for a volume-weighted average price of 1,400.75 p. All shares purchased will be held in treasury.

Since the non-discretionary mandate commenced on 4 June 2025 the company has acquired 9,978,493 ordinary shares. After the latest purchase GSK’s treasury stock rises to 228,112,876 shares, representing 5.58 % of total voting rights. The number of shares outstanding (excluding treasury) stands at 4,087,268,974, which is the new denominator for disclosure under the UK FCA’s DTR 5 rules.

No changes to the size or terms of the authorised buy-back were announced; the filing supplies the customary trading-venue and time-stamp breakdown required under UK regulation.

GSK plc filed a Form 6-K disclosing the latest execution under its ongoing share repurchase programme.

• Shares repurchased: 491,972 ordinary shares on 03 July 2025.
• Price range: 1,380.50 p – 1,411.00 p; VWAP: 1,396.15 p.
• Programme history: Since the non-discretionary agreement with Merrill Lynch International on 04 June 2025, the company has bought back 9,493,915 shares.
• Treasury position: After this purchase GSK holds 227,628,298 shares in treasury, equal to 5.57 % of total voting rights.
• Shares outstanding (ex-treasury): 4,087,741,901.
• The repurchase volume on 03 July represents around 0.012 % of shares in issue, while cumulative June–July purchases equal roughly 0.23 %.

The filing provides the standard denominator for Disclosure Guidance and Transparency Rule (DTR) calculations and lists each individual trade executed on the London Stock Exchange. No other financial, operational or strategic information is included.

Rocket Companies, Inc. (NYSE: RKT) has filed Amendment No. 1 to its Form S-4 to register shares for the proposed acquisition of Mr. Cooper Group Inc. (NASDAQ: COOP). The deal, executed 31 March 2025, will be effected through a two-step merger in which:

• Each Mr. Cooper share will be converted into 11 shares of Rocket Class A common stock plus cash in lieu of fractional shares.
• Mr. Cooper shareholders will also receive a pre-closing special cash dividend of $2.00 per share.

The fixed 11:1 exchange ratio represents a ~35 % premium to Mr. Cooper’s 30-day VWAP prior to announcement. Post-close, former Mr. Cooper holders are expected to own roughly 25 % of Rocket’s Class A stock (after giving effect to Rocket’s pending Redfin acquisition).

Rocket’s board unanimously approved the transaction and the associated share issuance; Rock Holdings Inc. (79 % voting power) has already delivered written consent, so no further Rocket shareholder vote is required. Mr. Cooper, however, must secure majority approval at a special virtual meeting; its board unanimously recommends the deal.

Financing & Structure:• Rocket obtained $4 bn of senior unsecured notes (2030 & 2033) and retains a $950 m commitment to refinance Mr. Cooper debt and pay fees. • Termination fees: Rocket pays $500 m if it walks; Mr. Cooper pays ~$306.9 m under specified scenarios. • No appraisal rights for Mr. Cooper holders.

Governance: A separate letter agreement ensures that two Mr. Cooper-designated directors join Rocket’s board for at least three years, with protections against removal.

Regulatory & Timing: Parties target Q4 2025 closing, subject to customary regulatory approvals and Mr. Cooper shareholder vote.

Investment Takeaways: The deal expands Rocket’s mortgage servicing footprint, but increases share count well above the 20 % NYSE threshold, diluting existing RKT holders. Mr. Cooper investors lock in a cash dividend and a sizeable premium but will face exposure to Rocket’s share performance until closing.

Dynatronics Corp. (DYNT) – Insider Form 4 filing dated 07/02/2025 details an equity transaction by long-time director and >10% shareholder Stuart M. Essig.

Nature of the transaction: Code “J” indicates a non-open-market event. The company paid the quarterly dividend on its 8% Preferred Stock in the form of DYNT common shares, valued at 90% of the 10-day average closing bid price. At a referenced value of $0.0655 per share, Mr. Essig received the stock rather than cash.

Shares received:

• Direct account: 870,203 new common shares
• Family trust (indirect): 174,652 new common shares
• Total acquired: 1,044,855 shares

Post-transaction holdings: Essig now directly owns 3,559,764 DYNT shares and indirectly owns 695,616 shares through a family trust.

The acquisition arises from a routine dividend payment rather than an elective open-market purchase, yet it still increases insider ownership and may align interests with common shareholders. No derivative securities were reported.